Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Inks $10M Secured Credit Agreement

NEW YORK – HTG Molecular Diagnostics said on Thursday that it has entered into a $10 million senior term loan agreement with Silicon Valley Bank.

The Tucson, Arizona-based firm used the proceeds to pay off HTG's $7.0 million principal amount term loan with MidCap Financial and its $3.0 million principal amount subordinated convertible promissory note held by Qiagen North American Holdings.

The senior term loan is for 42 months, with interest only payments through June 30, 2021, in addition to six additional months under specific conditions.

"As we continue to execute our strategy of growing our core profile business, building our portfolio with biopharma, and advancing our profiling product toward a diagnostic menu strategy, we believe that our relationship with SVB will be instrumental in allowing us to realize our value-building initiatives," Shaun McMeans, senior VP and CFO of HTG, said in a statement.

In addition, the $3.2 million of restricted cash previously held in escrow under HTG's prior senior credit facility has been released and is available for use in the firm's operations, the company said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.